Anti-Tumor Effects of Ganoderma lucidum (Reishi) in Inflammatory Breast Cancer in In Vivo and In Vitro Models

Suarez-Arroyo, Ivette J.; Rosario-Acevedo, Raysa; Aguilar-Perez, Alexandra; Clemente, Pedro L.; Cubano, Luis A.; Serrano, Juan; Schneider, Robert J.; Martínez-Montemayor, Michelle M.
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
The medicinal mushroom Ganoderma lucidum (Reishi) was tested as a potential therapeutic for Inflammatory Breast Cancer (IBC) using in vivo and in vitro IBC models. IBC is a lethal and aggressive form of breast cancer that manifests itself without a typical tumor mass. Studies show that IBC tissue biopsies overexpress E-cadherin and the eukaryotic initiation factor 4GI (eIF4GI), two proteins that are partially responsible for the unique pathological properties of this disease. IBC is treated with a multimodal approach that includes non-targeted systemic chemotherapy, surgery, and radiation. Because of its non-toxic and selective anti-cancer activity, medicinal mushroom extracts have received attention for their use in cancer therapy. Our previous studies demonstrate these selective anti-cancer effects of Reishi, where IBC cell viability and invasion, as well as the expression of key IBC molecules, including eIF4G is compromised. Thus, herein we define the mechanistic effects of Reishi focusing on the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, a regulator of cell survival and growth. The present study demonstrates that Reishi treated IBC SUM-149 cells have reduced expression of mTOR downstream effectors at early treatment times, as we observe reduced eIF4G levels coupled with increased levels of eIF4E bound to 4E-BP, with consequential protein synthesis reduction. Severe combined immunodeficient mice injected with IBC cells treated with Reishi for 13 weeks show reduced tumor growth and weight by ∼50%, and Reishi treated tumors showed reduced expression of E-cadherin, mTOR, eIF4G, and p70S6K, and activity of extracellular regulated kinase (ERK1/2). Our results provide evidence that Reishi suppresses protein synthesis and tumor growth by affecting survival and proliferative signaling pathways that act on translation, suggesting that Reishi is a potential natural therapeutic for breast and other cancers.


Related Articles

  • Induction of apoptosis in MCF-7 human breast cancer cells by Khz (fusion of Ganoderma lucidum and Polyporus umbellatus mycelium). TAE HWAN KIM; JU SUNG KIM; ZOO HAYE KIM; REN BIN HUANG; YOUNG LYE CHAE; REN SHENG WANG // Molecular Medicine Reports;2016, Vol. 13 Issue 2, p1243 

    Khz (fusion of Ganoderma lucidum and Polyporus umbellatus), isolated from the mycelia of G. lucidum and P. umbellatus, exerts anti-proliferative effects against malignant cells; however, its activity against human breast cancer cells remains to be elucidated. In the present study, cell...

  • Further improvement in ganoderic acid production in static liquid culture of Ganoderma lucidum by integrating nitrogen limitation and calcium ion addition. Li, Huan-Jun; Zhang, De-Huai; Han, Li-Liang; Yu, Xuya; Zhao, Peng; Li, Tao; Zhong, Jian-Jiang; Xu, Jun-Wei // Bioprocess & Biosystems Engineering;Jan2016, Vol. 39 Issue 1, p75 

    To further improve the ganoderic acid (GA) production, a novel integrated strategy by combining nitrogen limitation and calcium ion addition was developed. The effects of the integrated combination on the content of GA-T (one powerful anticancer compound), their intermediates (squalene and...

  • NEW AWARENESS ON MUSHROOMS AND CANCER: FOCUSING ON GANODERMA LUCIDUM AND BREAST CANCER. Chen, Alice W. // Current Topics in Nutraceutical Research;Nov2011, Vol. 9 Issue 4, p155 

    Ganoderma lucidum extract (GL extract) shows potential antitumor and chemoprevention effects on three types ofbreast cancer: estrogen-receptor dependent, estrogen-receptor independent, and inflammatory. Such positive effects are primarily due to the bioactive constituents in the GL extract,...

  • Breast cancer: The search for the cure continues. Magill-Lewis, Jillene // Drug Topics;5/5/2003 Supplement, Vol. 147 Issue 9, p19S 

    Discusses the continuous search for the treatment of breast cancer. Epidemiology of the disease in the U.S.; Drugs used to treat breast cancer; Efforts of researchers to make current drugs more effective and less toxic; Major concern on metastatic breast cancer.

  • Focus on docetaxel: A new antineoplastic agent approved by the FDA for the treatment of locally... Martin, William R. // Formulary;Oct96, Vol. 31 Issue 10, p891 

    Evaluates the effectiveness of docetaxel, an antineoplastic agent approved by the Food and Drug Administration for the treatment of locally advanced or metastatic breast cancer. Chemistry; Pharmacology; Pharmacokinetics; Result of clinical trials; Formulary considerations; Drug interactions;...

  • Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Tsavaris, N.; Kosmas, C.; Vadiaka, M.; Kanelopoulos, P.; Boulamatsis, D. // British Journal of Cancer;7/1/2002, Vol. 87 Issue 1, p21 

    Besides cytotoxicity, taxanes induce other biological effects, especially in the immune system. Taxanes have demonstrated immunostimulatory effects against neoplasms, supporting the idea that these agents suppress cancer through several mechanisms and not solely through inhibiting cell division....

  • Ixabepilone Injection (Ixempra). Elliott, William T.; Chan, James // Internal Medicine Alert;12/15/2007, Vol. 29 Issue 23, p181 

    The FDA has approved a new drug for the treatment of advanced breast cancer. Ixabepilone is a microtubule inhibitor in the class of epothilones. The drug was approved by priority review and is manufactured by Baxter Oncology GmBH in Germany and marketed by Bristol-Myers Squibb as Ixempra.â„¢...

  • Breast cancer patients now have a new option. Cerrato, Paul L. // RN;May96, Vol. 59 Issue 5, p77 

    Reports that the antineoplastic agent goserelin (Zoladex) could be used in the treatment of breast cancer. How the drug works; Details on the side effects of the drug.

  • Arimidex Results Expand Anticancer Class. Krause, Carey // Chemical Market Reporter;9/16/2002, Vol. 262 Issue 9, p14 

    Reports the approval of AstraZenica Plc's supplemental drug application for Arimidex as an adjuvant treatment of postmenopausal breast cancer. Risk reduction for breast cancer recurrence; Replacement of Nolvadex sales; Arimidex sales in 2002.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics